Related Experiment Videos
Hormone therapy for prostate cancer: a topical perspective
1Section of Urologic Oncology, Cleveland Clinic Foundation, Ohio 44195, USA.
Urology
|January 1, 1996
Summary
Antiandrogen agents, like flutamide, are increasingly used earlier for prostate cancer. Future research will determine if new agents like bicalutamide offer improved benefits for prostatic diseases.
Area of Science:
- Oncology
- Pharmacology
Background:
- Antiandrogenic agents have evolved in treating prostatic diseases.
- Flutamide, a nonsteroidal antiandrogen, is used with castration for metastatic prostate cancer.
Purpose of the Study:
- To explore the expanding roles of antiandrogens in prostatic disease management.
- To investigate the potential benefits of nilutamide and bicalutamide compared to flutamide.
- To assess the future applications of antiandrogens in earlier disease stages and high-risk patients.
Main Methods:
- Review of clinical trials and existing literature on antiandrogen therapy.
- Analysis of efficacy, safety, and dosing profiles of flutamide, nilutamide, and bicalutamide.
- Exploration of potential applications in prostatic intraepithelial neoplasia.
Main Results:
- Flutamide is currently the sole nonsteroidal antiandrogen available in the US.
- Nilutamide and bicalutamide await FDA decisions on their efficacy and safety.
- A trend exists towards earlier use of antiandrogens due to improved cancer detection.
Conclusions:
- Further research is needed to define the optimal roles for antiandrogens in prostate cancer and related conditions.
- The potential of new agents like bicalutamide for earlier disease stages requires investigation.
- Understanding safety, activity, and dosing is crucial for expanding antiandrogen use.